Table 2 Associations of APOE2 and APOE4 with neuritic plaque score, AD-tau, and AGD-tau
From: Impact of APOE on amyloid and tau accumulation in argyrophilic grain disease and Alzheimer’s disease
Variable | APOE2 present | APOE2 absent | Unadjusted analysis | Adjusting for age and sex | ||||
|---|---|---|---|---|---|---|---|---|
N | Median (minimum, maximum) or No. (%) of subjects | N | Median (minimum, maximum) or No. (%) of subjects | Estimate (95% CI) | P-value | Estimate (95% CI) | P-value | |
Neuritic plaque score | 45 | 308 | 0.44 (0.25, 0.78) | 0.005 | 0.49 (0.28, 0.87) | 0.015 | ||
0 | 20 (44.4%) | 60 (19.5%) | ||||||
1 | 4 (8.9%) | 62 (20.1%) | ||||||
2 | 10 (22.2%) | 76 (24.7%) | ||||||
3 | 11 (24.4%) | 110 (35.7%) | ||||||
AD-tau | 45 | 16 (35.6%) | 302 | 181 (59.9%) | 0.37 (0.19, 0.70) | 0.003 | 0.40 (0.20, 0.78) | 0.007 |
AGD-tau | 45 | 11 (24.4%) | 308 | 40 (13.0%) | 2.17 (0.98, 4.51) | 0.045 | 1.89 (0.84, 4.00) | 0.11 |
Variable | APOE4 present | APOE4 absent | Unadjusted analysis | Adjusting for age and sex | ||||
|---|---|---|---|---|---|---|---|---|
N | Median (minimum, maximum) or No. (%) of subjects | N | Median (minimum, maximum) or No. (%) of subjects | Estimate (95% CI) | P-value | Estimate (95% CI) | P-value | |
Neuritic plaque score | 152 | 201 | 5.31 (3.51, 8.05) | < 0.001 | 4.86 (3.17, 7.46) | < 0.001 | ||
0 | 7 (4.6%) | 73 (36.3%) | ||||||
1 | 26 (17.1%) | 40 (19.9%) | ||||||
2 | 37 (24.3%) | 49 (24.4%) | ||||||
3 | 82 (53.9%) | 39 (19.4%) | ||||||
AD-tau | 148 | 120 (81.1%) | 199 | 77 (38.7%) | 6.79 (4.16, 11.36) | < 0.001 | 6.34 (3.83, 10.76) | < 0.001 |
AGD-tau | 152 | 13 (8.6%) | 201 | 38 (18.9%) | 0.40 (0.20, 0.76) | 0.007 | 0.49 (0.24, 0.95) | 0.041 |